1
A comparative investigation of the operating characteristics demonstrates the favorable properties of the proposed approach.
2
Conclusions: Sunitinib exhibited advantageous pharmacokinetic and dispositional properties in non-clinical species, translating into favorable properties in humans.
3
Our data support a model in which the interplay of these features underlies the favorable properties of Bz-423.
4
These applications are possible because of the highly favorable properties of gold nanostructures, many of which can be tailored for specific applications.